Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

sections
  • 1 of 1

Millions of patients — including the prime minister herself — could be “seriously disadvantaged” by disruption to the drug supply chain if the UK exits the EU without a deal, the head of the UK’s medicines regulator has said.

Michael Rawlins, chair of the MHRA, says the government needs to work out how Brexit is going to work before drug supply issues arise

Source  Courtesy of Michael Rawlins